The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

L.t

Cavitation/necrosis of lung tumor or metastases

Publications

Nakano K, Motoi N, Tomomatsu J, Gokita T, Ae K, Tanizawa T, Matsumoto S, Takahashi S

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis.

BMC cancer 2016 Sep 23;16;750 — 2016 Sep 23 — 750

Leuzzi G, Alessandrini G, Ferraresi V, Ferretti G, Forcella D, Facciolo F

Bilateral spontaneous pneumothorax and massive pneumomediastinum under Pazopanib therapy.

Thoracic cancer 2015 Jan;6;110-1 — 2015 Jan — 110-1

Verschoor AJ, Gelderblom H

Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series.

Clinical sarcoma research 2014;4;14 — 2014 — 14